BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), an innovative biopharmaceutical company, is developing a universal flu vaccine designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. BiondVax’s go-to-market strategy for its lead candidate, M-001, is to initially obtain regulatory approval for its use as a primer to a pandemic or seasonal vaccine; following the accumulation of enough data, BiondVax will test and gain approval for its use as a universal standalone vaccine. For more information, visit the company’s website at www.biondvax.com.